查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1609186

非侵入性液态切片市场：按类型、技术和最终用户划分 - 全球预测 2025-2030

Non-Invasive Liquid Biopsy Market by Type (Assay Kits, Instruments, Services), Technology (Next Generation Sequencing (NGS), RT-PCR and dPCR), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，非侵入性液态切片市场价值为10.1亿美元，预计2024年将达到11.9亿美元，复合年增长率为18.10%，到2030年将达到32.5亿美元。

非侵入性液态切片是一种用于检测和监测癌症的尖端诊断方法，为传统组织切片检查提供了一种侵入性较小的替代方案。分析血液等体液中的循环性肿瘤细胞(CTC)、无细胞 DNA (cfDNA) 和 RNA，无需手术介入即可提供肿瘤动态的重要见解。对非侵入性液态切片的需求解决了组织切片检查的局限性，例如采样偏差和潜在的手术併发症，并且能够促进癌症的早期检测、监测治疗效果和检测復发性疾病。其应用涵盖肿瘤学、个人化医疗和产前检测，并用于医院、诊断中心和学术机构。关键的成长要素包括基因组学和蛋白​​质组学的进步、癌症发生率的增加以及对微创诊断技术的需求增加。此外，研究和开发活动的迅速增加以及对癌症早期检测的认识不断提高正在激活市场。

主要市场统计
基准年[2023] 10.1亿美元
预测年份 [2024] 11.9亿美元
预测年份 [2030] 32.5亿美元
复合年增长率（%） 18.10%

然而，挑战包括高成本、监管复杂性以及测试敏感性和特异性问题。为了克服这些限制，必须制定标准化通讯协定并透过强有力的检验研究证明临床效用。市场相关人员应专注于创新分子诊断技术，提高测试准确性，并整合人工智慧和机器学习进行资料分析。生物製药公司、研究机构和医疗保健提供者之间的伙伴关係和合作对于利用专业知识和扩大市场范围至关重要。还存在将应用扩展到其他疾病类型、改进多参数检测以及开发即时液态切片设备的机会。投资扩大我们对肿瘤生物学和抗药性机制的理解可以进一步提升液态切片作为癌症管理的变革工具的地位。市场充满活力且竞争激烈，需要持续创新和策略联盟来驾驭不断变化的格局并最大限度地实现业务成长。

市场动态：快速发展的非侵入性液态切片市场的关键市场洞察

非侵入性液态切片市场正在因供需的动态相互作用而发生转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症发生率和盛行率上升
    • 对非侵入性诊断方法的日益偏好
  • 市场限制因素
    • 先进的非侵入性液态切片高成本
  • 市场机会
    • 人工智慧与非侵入性液态切片相结合
    • 增加对先进医疗基础设施的投资
  • 市场挑战
    • 不同技术和肿瘤类型缺乏标准化

波特五力：驾驭非侵入性液态切片市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对非侵入性液态切片市场的外部影响

外部宏观环境因素在塑造非侵入性液态切片市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解非侵入性液态切片市场的竞争格局

非侵入性液态切片市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵非侵入性液态切片市场供应商绩效评估

FPNV 定位矩阵是评估非侵入性液态切片市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了非侵入性液态切片市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对非侵入性液态切片市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率和盛行率上升
      • 对非侵入性诊断方法的兴趣日益浓厚
    • 抑制因素
      • 先进的非侵入性液态切片高成本
    • 机会
      • 人工智慧与非侵入性液态切片相结合
      • 增加对先进医疗基础设施的投资
    • 任务
      • 不同技术和肿瘤类型缺乏标准化
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章无创液态切片市场：按类型

  • 检测试剂套件
  • 装置
  • 服务

第七章无创液态切片市场：依技术分类

  • 次世代定序（NGS）
  • RT-PCR 和 dPCR

第八章无创液态切片市场：按最终用户分类

  • 学术研究中心
  • 临床诊断实验室
  • 医院

第九章美洲无创液态切片市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太无创液态切片市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲无创液态切片市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Angle PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocept, Inc.
  • DiaCarta, Inc.
  • Epic Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group Ltd.
  • Lucence Diagnostics Pte. Ltd.
  • LungLife AI, Inc.
  • Mdxhealth BV
  • MedGenome Labs Ltd.
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Nonacus Limited
  • Norgen Biotek Corporation
  • Oasis Diagnostics Corporation
  • OraSure Technologies, Inc
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-5C6F41F5B02E

The Non-Invasive Liquid Biopsy Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.19 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 3.25 billion by 2030.

Non-invasive liquid biopsy is a cutting-edge diagnostic method used for cancer detection and monitoring, providing a less invasive alternative to traditional tissue biopsies. It involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), or RNA in bodily fluids like blood, offering critical insights into tumor dynamics without the need for surgical procedures. The necessity of non-invasive liquid biopsies lies in their ability to facilitate early cancer detection, monitor treatment efficacy, and detect recurrent disease, addressing the limitations of tissue biopsies, such as sampling bias and potential surgical complications. Their applications span across oncology, personalized medicine, and prenatal testing, with usage in hospitals, diagnostic centers, and academic institutions. Key growth factors include advancements in genomics and proteomics, growing cancer prevalence, and increasing demand for minimally invasive diagnostic techniques. Additionally, the surge in research and development activities and growing awareness about early cancer detection are fueling the market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.19 billion
Forecast Year [2030] USD 3.25 billion
CAGR (%) 18.10%

However, challenges include high costs, regulatory complexities, and issues related to test sensitivity and specificity. Overcoming these limits will entail developing standardized protocols and demonstrating clinical utility through robust validation studies. Market players should focus on innovation in molecular diagnostic technologies, enhancing test accuracy, and integrating AI and machine learning for data analysis. Partnerships and collaborations between biopharma companies, research institutes, and healthcare providers are vital to leverage expertise and expand market reach. Opportunities exist in expanding applications to other disease types, improving multi-analyte detection, and developing point-of-care liquid biopsy devices. Investing in expanding the understanding of tumor biology and resistance mechanisms could further elevate liquid biopsy as a transformative tool in cancer management. The market is dynamic and competitive, requiring continuous innovation and strategic collaborations to navigate the evolving landscape and maximize business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Invasive Liquid Biopsy Market

The Non-Invasive Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence and prevalence of cancer
    • Increasing preference for noninvasive diagnostic procedures
  • Market Restraints
    • High cost associated with advanced non-invasive liquid biopsy
  • Market Opportunities
    • Integration of artificial intelligence with non-invasive liquid biopsy
    • Increasing investment for advanced healthcare infrastructure
  • Market Challenges
    • Lack of standardization across different techniques and tumor types

Porter's Five Forces: A Strategic Tool for Navigating the Non-Invasive Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Invasive Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Invasive Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Invasive Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Invasive Liquid Biopsy Market

A detailed market share analysis in the Non-Invasive Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Invasive Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Invasive Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Invasive Liquid Biopsy Market

A strategic analysis of the Non-Invasive Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Invasive Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocept, Inc., DiaCarta, Inc., Epic Sciences Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Lucence Diagnostics Pte. Ltd., LungLife AI, Inc., Mdxhealth BV, MedGenome Labs Ltd., Menarini Silicon Biosystems SpA, Merck KGaA, Nonacus Limited, Norgen Biotek Corporation, Oasis Diagnostics Corporation, OraSure Technologies, Inc, QIAGEN GmbH, Thermo Fisher Scientific Inc., and Zymo Research Corp..

Market Segmentation & Coverage

This research report categorizes the Non-Invasive Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Assay Kits, Instruments, and Services.
  • Based on Technology, market is studied across Next Generation Sequencing (NGS) and RT-PCR and dPCR.
  • Based on End-user, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and prevalence of cancer
      • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced non-invasive liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence with non-invasive liquid biopsy
      • 5.1.3.2. Increasing investment for advanced healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization across different techniques and tumor types
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Non-Invasive Liquid Biopsy Market, by Type

  • 6.1. Introduction
  • 6.2. Assay Kits
  • 6.3. Instruments
  • 6.4. Services

7. Non-Invasive Liquid Biopsy Market, by Technology

  • 7.1. Introduction
  • 7.2. Next Generation Sequencing (NGS)
  • 7.3. RT-PCR and dPCR

8. Non-Invasive Liquid Biopsy Market, by End-user

  • 8.1. Introduction
  • 8.2. Academic & Research Centers
  • 8.3. Clinical Diagnostic Laboratories
  • 8.4. Hospital

9. Americas Non-Invasive Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Non-Invasive Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Non-Invasive Liquid Biopsy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Angle PLC
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Bio-Techne Corporation
  • 4. Biocept, Inc.
  • 5. DiaCarta, Inc.
  • 6. Epic Sciences Inc.
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Guardant Health, Inc.
  • 9. Illumina, Inc.
  • 10. Integrated DNA Technologies, Inc.
  • 11. Laboratory Corporation of America Holdings
  • 12. Lonza Group Ltd.
  • 13. Lucence Diagnostics Pte. Ltd.
  • 14. LungLife AI, Inc.
  • 15. Mdxhealth BV
  • 16. MedGenome Labs Ltd.
  • 17. Menarini Silicon Biosystems SpA
  • 18. Merck KGaA
  • 19. Nonacus Limited
  • 20. Norgen Biotek Corporation
  • 21. Oasis Diagnostics Corporation
  • 22. OraSure Technologies, Inc
  • 23. QIAGEN GmbH
  • 24. Thermo Fisher Scientific Inc.
  • 25. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. NON-INVASIVE LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-INVASIVE LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NON-INVASIVE LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RT-PCR AND DPCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023